ARQ-197 (Tivantinib) is a selective and oral small-molecule inhibitor of c-Met with a minimal IC50 value of 0.1 μM. c-Met, a key cell surface receptor tyrosine kinase involved in diverse regulatory functions, is often aberrantly activated in human cancers. While the precise mechanism of action of ARQ-197 remains undefined, data from preclinical studies have demonstrated that ARQ-197 inhibits c-Met activation in numerous human tumor cell lines and specifically targets c-Met in various cancer types; uniquely, ARQ-197 inhibits c-Met in a non-ATP-competitive manner. Phase I/II clinical trials demonstrated promise in terms of both tolerability and tumor response. Intriguingly, dose-limiting adverse effects were hematological in nature. Combinational trials are also ongoing to take advantage of the signaling crosstalk between c-Met and other oncogenic signaling systems. Prioritization of the clinical development of c-Met inhibitors, such as ARQ-197, among different tumor disease types is a key challenge at present; an improved understanding of the prediction of molecular determinants in tumors with respect to c-Met kinase as the driver oncogenic receptor, and of the prediction of tumor response, is still urgently needed.
|Source||Mol Oncol (2015). Figure 1. ARQ-197|
|Cell Lines||PC9, PC9 GR4, HCC827, A549 and H3122 cells|
|Concentrations||10, 100, 1000 nM|
|Incubation Time||72 h|
|Results||As in A549 cells, no changes in AKT or ERK1/2 phosphorylation were detected in PC9 cells when treated with tivantinib, crizotinib or PHA-668752|
|Cell lines||SK-MEL-28, NCI-H661, NCI-H446, DLD-1, A549, SK-OV-3, NCI-H460, A375, NCI-H441, HT29, MKN-45, and MDA-MB-231 cells|
|Preparation method||Cell proliferation assay
Cells were seeded in 96-well plates overnight in a medium with 10% FBS. Each cell line was optimized for seeding cell number to ensure a similar degree of confluence at the end of the experiment in nontreated (control) wells. The next day, cells were treated with different concentrations of ARQ 197 for 24 hours at 37°C. After ARQ 197 treatment, the drug-containing medium was removed, and cells were washed twice with PBS and incubated in a drug-free medium for an additional 48 hours. Cells were then incubated and stained for 4 hours with the MTS reagent (final concentration of 0.5 mg/mL; Promega) per well and were lysed. The results were quantitated by spectrophotometry at λ = 450 nm.
|Incubation time||24 h|
|Animal models||athymic mice bearing HT29, MKN-45, or MDA-MB-231 tumor xenografts|
|Formulation||polyethylene glycol 400/20% Vitamin E tocopheryl polyethylene glycol succinate (60:40) at 30 mg/mL|
|Dosages||200 mg/kg for 5 consecutive days weekly for four cycles|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
Munshi N, et al. Mol Cancer Ther. 2010 Jun;9(6):1544-53. PMID: 20484018.
|Related c-Met Products|
CEP-40783 (RXDX-106) is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.
AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.